12 research outputs found
Massively parallel sequencing of enriched mitochondrial DNA in patients with clinical suspicion of mitochondrial disease
Mitochondrial disorders constitute a clinically and genetically heterogeneous group of diseases that arise as a result of dysfunction of the mitochondrial respiratory chain. They can be caused by mutations in either the nuclear or mitochondrial DNA. In this study, three patients with clinical suspicion of mitochondrial disease were investigated by whole exome sequencing (WES), identifying the homozygous splice site mutation SURF1 c.106+1G>C in patient 1. This mutation, which was demonstrated to cause skipping of exon 2 in SURF1, was concluded to be the genetic cause of the Leigh syndrome like phenotype in the patient. Patients 2 and 3 were further investigated by massively parallel sequencing (MSP) of mtDNA from fibroblasts using a PCR free protocol for the preparation of mtDNA enriched samples. Sequencing resulted in uniform and ultra-deep coverage (>40,000) of the entire mtDNA genome, demonstrating that the PCR free approach is the method of choice when analyzing mitochondrial DNA by MSP. In parallel, analysis of mtDNA from muscle from patient 3 revealed the novel and nearly homoplastic deletion m.6211_8681del, which was concluded to be the cause of disease in the patient. This deletion was also identified in mtDNA from the patient s blood and skin tissues, but it was present in too low levels of heteroplasmy to be detected by MSP
Longitudinal Transcriptomic Analysis of Human Cortical Spheroids Identifies Axonal Dysregulation in the Prenatal Brain as a Mediator of Genetic Risk for Schizophrenia
BACKGROUND: Schizophrenia (SCZ) has a known neurodevelopmental etiology, but limited access to human
prenatal brain tissue hampers the investigation of basic disease mechanisms in early brain development. Here, we
elucidate the molecular mechanisms contributing to SCZ risk in a disease-relevant model of the prenatal human brain.
METHODS: We generated induced pluripotent stem cellâderived organoids, termed human cortical spheroids (hCSs),
from a large, genetically stratified sample of 14 SCZ cases and 14 age- and sex-matched controls. The hCSs were
differentiated for 150 days, and comprehensive molecular characterization across 4 time points was carried out.
RESULTS: The transcriptional and cellular architecture of hCSs closely resembled that of fetal brain tissue at 10 to 24
postconception weeks, showing strongest spatial overlap with frontal regions of the cerebral cortex. A total of 3520
genes were differentially modulated between SCZ and control hCSs across organoid maturation, displaying a significant contribution of genetic loading, an overrepresentation of risk genes for autism spectrum disorder and SCZ,
and the strongest enrichment for axonal processes in all hCS stages. The two axon guidance genes SEMA7A and
SEMA5A, the first a promoter of synaptic functions and the second a repressor, were downregulated and upregulated, respectively, in SCZ hCSs. This expression pattern was confirmed at the protein level and replicated in a large
postmortem sample.
CONCLUSIONS: Applying a disease-relevant model of the developing fetal brain, we identified consistent
dysregulation of axonal genes as an early risk factor for SCZ, providing novel insights into the effects of genetic
predisposition on the neurodevelopmental origins of the disorder
Dose-dependent transcriptional effects of lithium and adverse effect burden in a psychiatric cohort
Lithium is the first-line treatment for bipolar disorder (BD), but there is a large variation in response rate and adverse effects. Although the molecular effects of lithium have been studied extensively, the specific mechanisms of action remain unclear. In particular, the molecular changes underlying lithium adverse effects are little known. Multiple linear regression analyses of lithium serum concentrations and global gene expression levels in whole blood were carried out using a large case-control sample (n = 1450). Self-reported adverse effects of lithium were assessed with the âUdvalg for Kliniske Undersøgelserâ (UKU) adverse effect rating scale, and regression analysis was used to identify significant associations between lithium-related genes and six of the most common adverse effects. Serum concentrations of lithium were significantly associated with the expression levels of 52 genes (FDR < 0.01), largely replicating previous results. We found 32 up-regulated genes and 20 down-regulated genes in lithium users compared to non-users. The down-regulated gene set was enriched for several processes related to the translational machinery. Two adverse effects were significantly associated (p < 0.01) with three or more lithium-associated genes: tremor (FAM13A-AS1, FAR2, ITGAX, RWDD1, and STARD10) and xerostomia (ANKRD13A, FAR2, RPS8, and RWDD1). The adverse effect association with the largest effect was between CAMK1D expression and nausea/vomiting. These results suggest putative transcriptional mechanisms that may predict lithium adverse effects, and could thus have a large potential for informing clinical practice.publishedVersio
Transcriptional and functional effects of lithium in bipolar disorder iPSC-derived cortical spheroids
Lithium (Li) is recommended for long-term treatment of bipolar disorder (BD). However, its mechanism of action is still poorly understood. Induced pluripotent stem cell (iPSC)-derived brain organoids have emerged as a powerful tool for modeling BD-related disease mechanisms. We studied the effects of 1âmM Li treatment for 1 month in iPSC-derived human cortical spheroids (hCS) from 10 healthy controls (CTRL) and 11 BD patients (6 Li-responders, Li-R, and 5 Li non-treated, Li-N). At day 180 of differentiation, BD hCS showed smaller size, reduced proportion of neurons, decreased neuronal excitability and reduced neural network activity compared to CTRL hCS. Li rescued excitability of BD hCS neurons by exerting an opposite effect in the two diagnostic groups, increasing excitability in BD hCS and decreasing it in CTRL hCS. We identified 132 Li-associated differentially expressed genes (DEGs), which were overrepresented in sodium ion homeostasis and kidney-related pathways. Moreover, Li regulated secretion of pro-inflammatory cytokines and increased mitochondrial reserve capacity in BD hCS. Through long-term Li treatment of a human 3D brain model, this study partly elucidates the functional and transcriptional mechanisms underlying the clinical effects of Li, such as rescue of neuronal excitability and neuroprotection. Our results also underscore the substantial influence of treatment duration in Li studies. Lastly, this study illustrates the potential of patient iPSC-derived 3D brain models for precision medicine in psychiatry.publishedVersio
Loss-of-function variants in the schizophrenia risk gene SETD1A alter neuronal network activity in human neurons through the cAMP/PKA pathway
Heterozygous loss-of-function (LoF) mutations in SETD1A, which encodes a subunit of histone H3 lysine 4 methyltransferase, cause a neurodevelopmental syndrome and increase the risk for schizophrenia. Using CRISPR-Cas9, we generate excitatory/inhibitory neuronal networks from human induced pluripotent stem cells with a SETD1A heterozygous LoF mutation (SETD1A+/â). Our data show that SETD1A haploinsufficiency results in morphologically increased dendritic complexity and functionally increased bursting activity. This network phenotype is primarily driven by SETD1A haploinsufficiency in glutamatergic neurons. In accordance with the functional changes, transcriptomic profiling reveals perturbations in gene sets associated with glutamatergic synaptic function. At the molecular level, we identify specific changes in the cyclic AMP (cAMP)/Protein Kinase A pathway pointing toward a hyperactive cAMP pathway in SETD1A+/â neurons. Finally, by pharmacologically targeting the cAMP pathway, we are able to rescue the network deficits in SETD1A+/â cultures. Our results demonstrate a link between SETD1A and the cAMP-dependent pathway in human neurons.publishedVersio
Polygenic overlap with body-mass index improves prediction of treatment-resistant schizophrenia
Treatment resistant schizophrenia (TRS) is characterized by repeated treatment failure with antipsychotics. A recent genome-wide association study (GWAS) of TRS showed a polygenic architecture, but no significant loci were identified. Clozapine is shown to be the superior drug in terms of clinical effect in TRS; at the same time it has a serious side effect profile, including weight gain. Here, we sought to increase power for genetic discovery and improve polygenic prediction of TRS, by leveraging genetic overlap with Body Mass Index (BMI). We analysed GWAS summary statistics for TRS and BMI applying the conditional false discovery rate (cFDR) framework. We observed cross-trait polygenic enrichment for TRS conditioned on associations with BMI. Leveraging this cross-trait enrichment, we identified 2 novel loci for TRS at cFDR <0.01, suggesting a role of MAP2K1 and ZDBF2. Further, polygenic prediction based on the cFDR analysis explained more variance in TRS when compared to the standard TRS GWAS. These findings highlight putative molecular pathways which may distinguish TRS patients from treatment responsive patients. Moreover, these findings confirm that shared genetic mechanisms influence both TRS and BMI and provide new insights into the biological underpinnings of metabolic dysfunction and antipsychotic treatment.publishedVersio
Transcriptional Modeling of Severe Mental Illnesses
Schizophrenia (SCZ) and bipolar disorder (BD) are severe mental illnesses characterized by a heterogenous clinical presentation and a complex underlying pathophysiology which is not fully understood. Genetic studies have identified many risk variants, the majority of which are located within non-coding regions of the genome, suggesting primarily a role in gene expression regulation.
In this thesis, microarrays and RNA sequencing were used for transcriptome profiling in various experimental models. The aim was to explore the transcriptional underpinnings of three clinical aspects of SCZ and BD: verbal memory, lithium treatment, and inflammatory modulation.
Memory performance was inversely associated with peripheral TCN1 expression in both SCZ and BD. TCN1 is involved in vitamin B12 transportation and cellular uptake, and the finding may thus have important implications for the diagnosis and treatment of vitamin B12-related conditions.
Lithium treatment in rodent brains was associated with the differential expression of GRIN2A, which encodes a subunit of glutamate-mediated NMDA receptors, the most important excitatory receptors in the brain. This finding lends support to the glutamatergic hypothesis of BD.
Inflammatory modulation was associated with a reduced expression of CCL20 in astrocytes derived from SCZ patients. Astrocytes secrete the chemokine CCL20 to attract regulatory T cells to the site of inflammation in order to terminate the immune response, suggesting that a dysfunctional astrocyte-mediated recruitment of T cells may be involved in the over-active immune state seen in SCZ patients.
In summary, we identify specific transcriptional mechanisms that may underlie the clinical aspects under study. Some of these findings have potential clinical relevance or may inform the development of novel therapeutic agents. These findings also further confirm that transcriptional mechanisms play a central role in the pathophysiology of SCZ and BD
A human iPSC-astroglia neurodevelopmental model reveals divergent transcriptomic patterns in schizophrenia
Abstract While neurodevelopmental abnormalities have been associated with schizophrenia (SCZ), the role of astroglia in disease pathophysiology remains poorly understood. In the present study, we used a human induced pluripotent stem cell (iPSC)-derived astrocyte model to investigate the temporal patterns of astroglia differentiation during developmental stages critical for SCZ using RNA sequencing. The model generated astrocyte-specific gene expression patterns during differentiation that corresponded well to astroglia-specific expression signatures of in vivo cortical fetal development. Using this model we identified SCZ-specific expression dynamics, and found that SCZ-associated differentially expressed genes were significantly enriched in the medial prefrontal cortex, striatum, and temporal lobe, targeting VWA5A and ADAMTS19 . In addition, SCZ astrocytes displayed alterations in calcium signaling, and significantly decreased glutamate uptake and metalloproteinase activity relative to controls. These results implicate novel transcriptional dynamics in astrocyte differentiation in SCZ together with functional changes that are potentially important biological components of SCZ pathology
Dose-dependent transcriptional effects of lithium and adverse effect burden in a psychiatric cohort
Lithium is the first-line treatment for bipolar disorder (BD), but there is a large variation in response rate and adverse effects. Although the molecular effects of lithium have been studied extensively, the specific mechanisms of action remain unclear. In particular, the molecular changes underlying lithium adverse effects are little known. Multiple linear regression analyses of lithium serum concentrations and global gene expression levels in whole blood were carried out using a large case-control sample (n = 1450). Self-reported adverse effects of lithium were assessed with the âUdvalg for Kliniske Undersøgelserâ (UKU) adverse effect rating scale, and regression analysis was used to identify significant associations between lithium-related genes and six of the most common adverse effects. Serum concentrations of lithium were significantly associated with the expression levels of 52 genes (FDR < 0.01), largely replicating previous results. We found 32 up-regulated genes and 20 down-regulated genes in lithium users compared to non-users. The down-regulated gene set was enriched for several processes related to the translational machinery. Two adverse effects were significantly associated (p < 0.01) with three or more lithium-associated genes: tremor (FAM13A-AS1, FAR2, ITGAX, RWDD1, and STARD10) and xerostomia (ANKRD13A, FAR2, RPS8, and RWDD1). The adverse effect association with the largest effect was between CAMK1D expression and nausea/vomiting. These results suggest putative transcriptional mechanisms that may predict lithium adverse effects, and could thus have a large potential for informing clinical practice
Loss-of-function variants in the schizophrenia risk gene SETD1A alter neuronal network activity in human neurons through the cAMP/PKA pathway
Heterozygous loss-of-function (LoF) mutations in SETD1A, which encodes a subunit of histone H3 lysine 4 methyltransferase, cause a neurodevelopmental syndrome and increase the risk for schizophrenia. Using CRISPR-Cas9, we generate excitatory/inhibitory neuronal networks from human induced pluripotent stem cells with a SETD1A heterozygous LoF mutation (SETD1A+/â). Our data show that SETD1A haploinsufficiency results in morphologically increased dendritic complexity and functionally increased bursting activity. This network phenotype is primarily driven by SETD1A haploinsufficiency in glutamatergic neurons. In accordance with the functional changes, transcriptomic profiling reveals perturbations in gene sets associated with glutamatergic synaptic function. At the molecular level, we identify specific changes in the cyclic AMP (cAMP)/Protein Kinase A pathway pointing toward a hyperactive cAMP pathway in SETD1A+/â neurons. Finally, by pharmacologically targeting the cAMP pathway, we are able to rescue the network deficits in SETD1A+/â cultures. Our results demonstrate a link between SETD1A and the cAMP-dependent pathway in human neurons